Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385012 | 0.92 | TRPV1 (0.55) | TRPV1KDRFLT1F10EPHB4 | |
| SCHEMBL2384143 | 0.90 | TRPV1 (0.52) | TRPV1KDRFLT1F10EPHB4 | |
| SCHEMBL2385230 | 0.89 | TRPV1 (0.57) | TRPV1CHRM4KIT | |
| SCHEMBL2381611 | 0.89 | TRPV1 (0.57) | TRPV1CHRM4KIT | |
| SCHEMBL2384249 | 0.84 | TRPV1 (0.56) | TRPV1KDRFLT1 | |
| SCHEMBL2382673 | 0.83 | TRPV1 (0.42) | TRPV1KDRFLT1F10EPHB4 | |
| SCHEMBL2383360 | 0.83 | TRPV1 (0.52) | TRPV1KIT | |
| SCHEMBL2382825 | 0.83 | TRPV1 (0.51) | TRPV1KDRFLT1F10EPHB4 | |
| SCHEMBL2383930 | 0.82 | TRPV1 (0.44) | TRPV1KDRF10CACNA1GCACNA1H | |
| SCHEMBL2385139 | 0.81 | TRPV1 (0.57) | TRPV1KDRFLT1F10EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | TRPV1 4108/4885KDR 3/4885FLT1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.